Study of REM-422 in Patients With AML or Higher Risk MDS

Study of REM-422 in Patients With AML or Higher Risk MDS
Conditions: Myelodysplastic Syndromes; Higher Risk Myelodysplastic Syndromes; Acute Myeloid Leukemia; Acute Myeloid Leukemia Refractory

Interventions: Drug: REM-422

Sponsors: Remix Therapeutics

Not yet **RECRUITING NOW**

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

March 9, 2024Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine
Comments